Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.

Eur Heart J · 2021 · PMC7878011 · PMID 33459776

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

near-significantno p-value reported

For all of these reasons, for each of our three major hierarchical endpoints, we were able to demonstrate a significant or near-significant benefit of empagliflozin ( P -values ranging from 0.052 to 0.009), even when the analysis of the effect of empagliflozin was confined only to patients receiving sacubitril/valsartan.

also in 2,306 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.